Wall Street brokerages expect that Humana (NYSE:HUM) will post $3.21 earnings per share for the current fiscal quarter, according to Zacks. Six analysts have provided estimates for Humana’s earnings. The highest EPS estimate is $3.25 and the lowest is $3.18. Humana posted earnings of $2.75 per share during the same quarter last year, which indicates a positive year over year growth rate of 16.7%. The business is scheduled to report its next quarterly earnings report before the market opens on Wednesday, May 2nd.
According to Zacks, analysts expect that Humana will report full-year earnings of $13.86 per share for the current fiscal year, with EPS estimates ranging from $13.73 to $14.13. For the next financial year, analysts expect that the firm will post earnings of $16.42 per share, with EPS estimates ranging from $15.51 to $17.50. Zacks’ earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Humana.
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.00 by $0.06. Humana had a return on equity of 16.13% and a net margin of 4.55%. The company had revenue of $13.19 billion during the quarter, compared to analysts’ expectations of $13.14 billion. During the same quarter in the previous year, the company posted $2.34 earnings per share. The business’s revenue was up 2.4% on a year-over-year basis.
HUM has been the subject of a number of research analyst reports. Zacks Investment Research cut Humana from a “strong-buy” rating to a “hold” rating in a report on Friday, January 19th. Cowen restated a “buy” rating and set a $285.00 price objective on shares of Humana in a report on Wednesday, December 13th. Jefferies Group upgraded Humana from a “hold” rating to a “buy” rating and set a $221.00 price objective for the company in a report on Friday, January 12th. Oppenheimer boosted their price objective on Humana from $275.00 to $305.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. Finally, Leerink Swann boosted their price objective on Humana from $280.00 to $300.00 and gave the stock an “outperform” rating in a report on Thursday, February 8th. Seven analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $272.21.
In other Humana news, CEO Bruce D. Broussard sold 14,075 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $274.32, for a total transaction of $3,861,054.00. Following the completion of the transaction, the chief executive officer now directly owns 113,896 shares in the company, valued at $31,243,950.72. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Cynthia H. Zipperle sold 1,196 shares of the business’s stock in a transaction that occurred on Friday, March 9th. The shares were sold at an average price of $273.33, for a total transaction of $326,902.68. Following the transaction, the senior vice president now owns 7,771 shares of the company’s stock, valued at $2,124,047.43. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 31,660 shares of company stock valued at $8,668,218. Company insiders own 0.60% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Cambridge Investment Research Advisors Inc. raised its position in Humana by 18.8% during the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 3,372 shares of the insurance provider’s stock valued at $836,000 after purchasing an additional 534 shares in the last quarter. Certified Advisory Corp acquired a new position in Humana during the fourth quarter valued at approximately $109,000. Colonial Trust Advisors acquired a new position in Humana during the fourth quarter valued at approximately $13,780,000. Xact Kapitalforvaltning AB raised its position in Humana by 6.9% during the fourth quarter. Xact Kapitalforvaltning AB now owns 24,981 shares of the insurance provider’s stock valued at $6,197,000 after purchasing an additional 1,606 shares in the last quarter. Finally, OLD Mutual Customised Solutions Proprietary Ltd. raised its position in Humana by 41.8% during the fourth quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 9,159 shares of the insurance provider’s stock valued at $2,272,000 after purchasing an additional 2,700 shares in the last quarter. Institutional investors and hedge funds own 96.43% of the company’s stock.
Shares of NYSE:HUM opened at $286.84 on Friday. Humana has a 12-month low of $210.01 and a 12-month high of $293.35. The company has a market cap of $39,240.03, a PE ratio of 24.38, a PEG ratio of 1.54 and a beta of 0.97. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.85 and a quick ratio of 1.85.
Humana declared that its Board of Directors has approved a stock repurchase plan on Thursday, December 14th that permits the company to buyback $3.00 billion in shares. This buyback authorization permits the insurance provider to repurchase shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.
The business also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Friday, March 30th will be paid a $0.50 dividend. This is a boost from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 annualized dividend and a dividend yield of 0.70%. The ex-dividend date is Wednesday, March 28th. Humana’s payout ratio is 17.08%.
WARNING: “Analysts Expect Humana (HUM) to Announce $3.21 Earnings Per Share” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/11/analysts-expect-humana-hum-to-announce-3-21-earnings-per-share.html.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Get a free copy of the Zacks research report on Humana (HUM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.